Study on the pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in obesity-related atrial fibrillation based on network pharmacology and experimental verification

BACKGROUND: Obesity is an independently risk factor of atrial fibrillation (AF). It is likely that the global burden of AF will escalate due to the current obesity epidemic. Weight loss can effectively reduce the risk of AF, while sodium-glucose co-transporter 2 inhibitors (SGLT2i) can reduce body w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Qianqian, Wang, Peng, Zhao, Maoxiang, Hong, Jing, Zhang, Nan, Lin, Kun, Li, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170287/
https://www.ncbi.nlm.nih.gov/pubmed/37181345
http://dx.doi.org/10.21037/atm-23-1321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170287/
https://www.ncbi.nlm.nih.gov/pubmed/37181345
http://dx.doi.org/10.21037/atm-23-1321

Ejemplares similares